{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-23-000020","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2023-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.527787+00:00","generated_at":"2026-06-19T20:14:12.152912+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nurix reports FY2022 net loss $180.4M, cash $373M; NX-2127 shows clinical benefit in CLL","bullets":["Net loss for FY ended Nov 30, 2022: $180.4M ($3.71/shr) vs $117.2M ($2.73/shr) in FY2021; R&D expense $184.5M.","Cash and marketable securities at $373.0M on Nov 30, 2022, down from $432.9M at Nov 30, 2021; collaboration revenue $38.6M.","NX-2127 BTK degrader achieved clinical responses in heavily pretreated CLL patients with BTK inhibitor resistance mutations.","Initial PK/PD data for NX-5948 showed rapid, sustained BTK degradation; FDA clearance for US trial expansion received Dec 2022.","Nurix expects to present additional clinical data for NX-2127, NX-5948, and NX-1607 in 2H 2023; partnered 10 discovery programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-23-000020","json":"https://secwatch.observer/filing/0001549595-23-000020.json","markdown":"https://secwatch.observer/filing/0001549595-23-000020.md","text":"https://secwatch.observer/filing/0001549595-23-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000020/0001549595-23-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000020/nrix-20230209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T20:14:12.152912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7f40b0c5cce5b18facd4380b89bb612915c03a13","claim":"Nurix Therapeutics, Inc. reported financial results for the fourth quarter and fiscal year ended November 30, 2022.","evidence_excerpt":"On February 9, 2023, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal year ended November 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000020/0001549595-23-000020-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended November 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}